The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO WCGIC 2023 | The role of systemic treatment in early-stage hepatocellular carcinoma
Ghassan Abou-Alfa, MD, MBA, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the potential utility of systemic therapies in the management of early-stage hepatocellular carcinoma (HCC). Available adjuvant therapies in this space remain an unmet need, and the Phase III IMbrave050 trial (NCT04102098), which assessed adjuvant atezolizumab plus bevacizumab with active surveillance in patients with HCC, aims to provide a solution. Current findings suggest promising outcomes for patients that received adjuvant atezolizumab. This interview took place at the ESMO World Congress on Gastrointestinal Cancer (WCGIC) 2023 in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
